Loading...
An update on genomic-guided therapies for pediatric solid tumors
Tsui, P.C. Lee, Stephanie Liu, Z.W.Y. Ip, L.R.H. Piao, W. Chiang, A.K.S. Lui, V.W.Y.
Tsui, P.C.
Lee, Stephanie
Liu, Z.W.Y.
Ip, L.R.H.
Piao, W.
Chiang, A.K.S.
Lui, V.W.Y.
Publication Date
2017-06
End of Embargo
Supervisor
Rights
© 2017 Future Medicine Ltd. Reproduced in accordance with the publisher's self-archiving policy.
Peer-Reviewed
Yes
Open Access status
openAccess
Accepted for publication
2017
Institution
Department
Awarded
Embargo end date
Collections
Additional title
Abstract
Currently, out of the 82 US FDA-approved targeted therapies for adult cancer treatments, only three are approved for use in children irrespective of their genomic status. Apart from leukemia, only a handful of genomic-based trials involving children with solid tumors are ongoing. Emerging genomic data for pediatric solid tumors may facilitate the development of precision medicine in pediatric patients. Here, we provide an up-to-date review of all reported genomic aberrations in the eight most common pediatric solid tumors with whole-exome sequencing or whole-genome sequencing data (from cBioPortal database, Pediatric Cancer Genome Project, Therapeutically Applicable Research to Generate Effective Treatments) and additional non-whole-exome sequencing studies. Potential druggable events are highlighted and discussed so as to facilitate preclinical and clinical research in this area.
Version
Accepted manuscript
Citation
Tsui PC, Lee Y-F, Liu ZWY et al (2017) An update on genomic-guided therapies for pediatric solid tumors. Future Oncology. 13(15): 1345-1358.
Link to publisher’s version
Link to published version
Link to Version of Record
Type
Article